Cannabigerolic Acid (CBG-a) Research Dashboard
Double-blind human trials
Clinical human trials
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 23 studies associated with Cannabigerolic Acid (CBG-a).
Here is a small sampling of Cannabigerolic Acid (CBG-a) studies by title:
- Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants
- Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome
- Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation
- Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy
- Identification of Chemotypic Markers in Three Chemotype Categories of Cannabis Using Secondary Metabolites Profiled in Inflorescences, Leaves, Stem Bark, and Roots
Components of the Cannabigerolic Acid (CBG-a) Research Dashboard
- Top medical conditions associated with Cannabigerolic Acid (CBG-a)
- Proven effects in clinical trials for Cannabigerolic Acid (CBG-a)
- Receptors associated with Cannabigerolic Acid (CBG-a)
- Individual study details for Cannabigerolic Acid (CBG-a)
Ready to become a subscriber? Go to our PRICING page.
Members can filter by the following criteria:
- Study Type
- Organ Systems
- Study Result
- Year of Publication
Overview - Cannabigerolic Acid (CBG-a)
Description of Cannabigerolic Acid (CBG-a)
The plant-based (phytocannabinoid) Cannabigerolic-acid was discovered in 1965. It is the essential precursor to all other phytocannabinoids such as THC-A, CBD-A, CBG-A for example.
Cannabigerolic Acid (CBG-a) Properties and Effects
Cannabigerolic Acid (CBG-a) Receptor Binding
Weak affinity for CB1 (Ki 440 nM). Weak affinity for CB2 (Ki 337 nM).
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.